WO2006076015A3 - 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof - Google Patents

1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof Download PDF

Info

Publication number
WO2006076015A3
WO2006076015A3 PCT/US2005/014839 US2005014839W WO2006076015A3 WO 2006076015 A3 WO2006076015 A3 WO 2006076015A3 US 2005014839 W US2005014839 W US 2005014839W WO 2006076015 A3 WO2006076015 A3 WO 2006076015A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytosine
phosphonomethoxy
analogs
ethyl
compounds
Prior art date
Application number
PCT/US2005/014839
Other languages
French (fr)
Other versions
WO2006076015A2 (en
Inventor
James R Beadle
Karl Y Hostetler
Nadejda Valiaeva
Original Assignee
Univ California
James R Beadle
Karl Y Hostetler
Nadejda Valiaeva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, James R Beadle, Karl Y Hostetler, Nadejda Valiaeva filed Critical Univ California
Publication of WO2006076015A2 publication Critical patent/WO2006076015A2/en
Publication of WO2006076015A3 publication Critical patent/WO2006076015A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Abstract

Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections. The compounds provided herein are substituted and unsubstituted phosphonomethoxyethyl cytosine and lipophilic esters thereof.
PCT/US2005/014839 2004-04-30 2005-04-29 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof WO2006076015A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56732604P 2004-04-30 2004-04-30
US60/567,326 2004-04-30

Publications (2)

Publication Number Publication Date
WO2006076015A2 WO2006076015A2 (en) 2006-07-20
WO2006076015A3 true WO2006076015A3 (en) 2007-02-22

Family

ID=36636530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014839 WO2006076015A2 (en) 2004-04-30 2005-04-29 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof

Country Status (1)

Country Link
WO (1) WO2006076015A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535862A (en) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド Compounds, compositions and methods for the treatment of poxvirus infections
JP5320284B2 (en) * 2006-05-03 2013-10-23 キメリクス，インコーポレーテッド Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
MX2010008148A (en) 2008-01-25 2010-10-20 Chimerix Inc Methods of treating viral infections.
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
EP3216789A1 (en) 2010-02-12 2017-09-13 Chimerix, Inc. Methods of treating viral infection
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
CN107056838A (en) 2013-03-15 2017-08-18 加利福尼亚大学董事会 Acyclic nucleoside phosphonate diester
EP3194411B1 (en) 2014-09-15 2022-05-04 The Regents of the University of California Nucleotide analogs
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039724A2 (en) * 1999-12-03 2001-06-07 The Regents Of The University Of California, San Diego Phosphonate compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039724A2 (en) * 1999-12-03 2001-06-07 The Regents Of The University Of California, San Diego Phosphonate compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BULLER R M ET AL: "Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 318, no. 2, 20 January 2004 (2004-01-20), pages 474 - 481, XP004490185, ISSN: 0042-6822 *
HOLY ET AL: "Structure-Antiviral Activity Relationship in the Series of Pyrimidine and Purine N-[2-(2-Phosphonomethoxy)ethyl] Nucleotide Analogues. 1. Derivatives Substituted at the Carbon Atoms of the Base", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, 1999, pages 2064 - 2086, XP002215041, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2006076015A2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
WO2006076015A3 (en) 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
AP2005003366A0 (en) Pyrimidine derivatives for the prevention of HIV infection.
WO2008127364A3 (en) Antiviral compounds and use thereof
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
USD544103S1 (en) Blood or plasma treatment apparatus
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2006033709A3 (en) Novel nucleoside derivatives
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
USD592693S1 (en) Through-the-lens medical/dental loupes
WO2007084435A8 (en) Methods for treating hepatitis c
NO20064808L (en) Oral matrix formulations with licarbazepine
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2006064228A3 (en) Thiazolopyramidine compounds for the modulation of chemokine receptor activity
EP1944027A4 (en) Pharmaceutical composition for treatment or prevention of nephritis and method for producing same
WO2009021971A3 (en) Novel targets and compounds for therapeutic intervention of hiv infection
WO2004064757A3 (en) Absorption enhancing agents
WO2006085228A3 (en) 9a-carbamoyl-y-aminopropyl and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase